Dysmenorrhea Treatment Market Size, Share, Forecast 2022
                     Dysmenorrhea Treatment Market - Overview
Dysmenorrhea refers to the painful menstruation women experience during their monthly 
discharging periods. While it is normal for women to have mild abdominal cramps on the initial days 
of their menstruation, about 30% of women experience severe pain along with headaches and 
nausea that could be termed as Dysmenorrhea. Over the past decade, the prevalence of 
Dysmenorrhea is observed to be growing. Reasons could be environmental changes, change in diet, 
and lack of nutritious diet, etc.
However, the cause acting as the driving force to prevail these conditions is changing and unhealthy 
lifestyle. Today’s working women have to cope-up with physical as well as mental stress 
encountered at both the fronts – personal (family) and workplace. Growing awareness among 
women towards the fact that Dysmenorrhea can now be treated and the availability and accessibility 
of treatments are encouraging the increasing number of women to avail the advantages of these 
treatments. Resultantly, Dysmenorrhea market is growing pervasively, becoming a lucrative space.
Acknowledging the exponential growth the market perceives currently; Market Research Future 
(MRFR), in its recently published market forecast asserts that the global Dysmenorrhea Treatment 
Market will reach USD 8.40 Bn. by 2023, registering a striking CAGR of 12.28% throughout the 
forecast period (2017 – 2023). In 2016, the market had valued at USD 5.68 Bn.
List of Key Companies Covered in this report:
Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer 
AG (Germany), Focus Consumer Healthcare, LLC (US), Novartis AG (Switzerland), Pfizer, Inc. (US), 
Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France), Viatris Inc. (US)
Dysmenorrhea Treatment Market - Segmentations
MRFR has segmented the report into three key dynamics for an easy grasp and enhanced 
understanding:-
By Type: Primary and Secondary (Adenomyosis, Endometriosis, Uterine myomas, Cervical stenosis, 
Endometrial polyps, and Obstructive malformations of genital tract.).
By Treatment: Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Hormonal, and Combined Oral 
Contraceptive among others.
By End-User : Hospitals, Clinics, Diagnostic Centers, and Pharmaceutical Companies among 
Others.
By Regions: North America, Europe, APAC and Rest of the World.
Global Dysmenorrhea Treatment Market  - Competitive Landscape
The competitive market for Dysmenorrhea Treatment is fragmented with many large and small 
players operating in the market. Market players incorporate acquisition, collaboration, expansion, 
technology launch and strategic partnership. These players substantially invest in R&D and clinical 
trials to develop effective drugs.
To help accelerate pharmaceutical innovations and to gain a better understanding of the conditions, 
these pharma companies collaborate with academia and the biotech industry partners who can 
contribute cutting-edge technologies and specialized knowledge. These collaborations are one of 
the innovation strategies of market players. Companies can leverage the latest scientific knowledge
and translate it into innovative medicines through partnering. These partnerships can kindle the 
innovative impulses that advance medicine and benefit patients as well as partners.
Global Dysmenorrhea Treatment Market - Regional Analysis
Globally North America leads the Dysmenorrhea Treatment market with the significant market 
share. The Market is expected to grow phenomenally from 2017 to 2023. Attributing to the 
favorable reimbursement scenario and higher expenditure on healthcare the market is expected to 
perceive a healthy growth.
The factor contributing to the market growth include increasing prevalence of issues and disorders 
associated with women’s reproductive system fuelled by the changing lifestyle and growing 
awareness towards the availability of the treatments. The US, backed by the technological advances 
and availability of funding for the development of new therapeutics and treatment accounts for the 
major contributor to the market growth.
Europe emerging as a lucrative market for Dysmenorrhea Treatment will expand registering a 
phenomenal CAGR. The resurging economy in the region is expected to foster the regional market 
growth, increasing per capita healthcare expenditures. The financial support provided by private and 
governments bodies for R&D activities and new improved reimbursement policies in healthcare will 
fuel the Dysmenorrhea Treatment market in Europe.
Industry/Innovation/ Related News:
January 04, 2018 – Pfizer Inc. (US) a pharmaceutical conglomerate announced the partnership with 
23andMe (US), a privately held personal genomics and biotechnology company to aid understanding 
of depression, dysmenorrhea and the genetic heterogeneity of lupus and inflammatory bowel 
disease. Pfizer believes that such collaborations will help it to potentially usher in a new era of 
patient care defined by targeted research methods and ultimately better patient outcomes.
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries 
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research 
Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited), 
99 Hudson Street,5Th Floor, New York,
New York 10013